Our Approach

Ardelyx develops:

  • Innovative, non-systemic, small molecule therapeutics that work exclusively in the GI tract to treat cardio-renal, GI and metabolic diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas



Reduce systemic uptake, minimize side effects.

Program Indication Research Phase 1 Phase 2 Phase 3 Status Development and Commercial Rights
2a 2b 2a 2b
Tenapanor(NHE3 Inhibitor) IBS-C * *  * *  * *  Phase 3
Ready
Ardelyx
ESRD HyperPi *  *  *  *  *  *  Phase 2b
Completed
RDX022(Potassium Binder) Hyper-
kalemia
*  *  *  *  *  *  505[b][2] Ardelyx
RDX009(TGR5 agonist) IBD, Short
Bowel,
NASH
*  *  *  *  *  *  Research Ardelyx
RDX013(K+ channel modulator) Hyper-
kalemia
*  *  *  *  *  *  Research Ardelyx
RDX002 (NaP2b Inhibitor) ESRD
HyperPi
*  *  *  *  *  *  Research SANOFI